{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-254619","form_type":"8-K","ticker":"FULC","cik":"0001680581","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2025-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.132575+00:00","generated_at":"2026-05-17T01:40:22.510987+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Fulcrum Therapeutics Q3 loss $19.6M; pociredir 20mg cohort enrolled, data due year-end","bullets":["Cash, equivalents and marketable securities $200.6M; cash runway into 2028.","Net loss $19.6M in Q3 2025 versus $21.7M in Q3 2024; R&D spend $14.3M.","12 mg dose cohort of Phase 1b PIONEER trial showed dose-dependent HbF increase and VOC reduction.","Enrollment completed in 20 mg dose cohort (n=12); data expected by year-end 2025.","Plans to submit IND for bone marrow failure syndromes (DBA, 5q-, etc.) in Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-254619","json":"https://secwatch.observer/filing/0001193125-25-254619.json","markdown":"https://secwatch.observer/filing/0001193125-25-254619.md","text":"https://secwatch.observer/filing/0001193125-25-254619.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680581/000119312525254619/0001193125-25-254619-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680581/000119312525254619/fulc-20251029.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:40:22.510987+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}